What’s driving GSK higher today?

Traders Union
All News
Financial News
GSK Surges 6.81% to $1,756 Today

Highlights

GSK raised its 2025 guidance, now expecting turnover growth of 6% to 7%, core operating profit up 9% to 11%, and core EPS up 10% to 12% at constant exchange rates.
Q3 performance was driven by strong US sales, higher patient volume, and expansion in international markets including France, Spain, Italy, Australia, and Canada.
GSK advanced its respiratory and oncology R&D pipeline via acquisitions and licensing, and reaffirmed shareholder returns with a 16p Q3 dividend and £1.1 billion in share buybacks year-to-date.

Upbeat guidance and global expansion strengthen bullish investor sentiment

GSK reported strong Q3 2025 results on October 29, 2025, raising its guidance for the year with turnover growth of 6% to 7%, core operating profit growth of 9% to 11%, and core EPS growth of 10% to 12% at constant exchange rates. Performance was driven by higher US sales, increased patient volume, and expansion in key international markets such as France, Spain, Italy, Australia, and Canada. The company also advanced its R&D pipeline through acquisitions and licensing in respiratory and oncology, and reaffirmed its shareholder return plans with a 16p Q3 dividend and £1.1 billion in share buybacks year-to-date.

Anton Kharitonov, expert at Traders Union, highlights that GSK’s consistent outperformance of major moving averages and its solid Q3 earnings report have clearly improved market sentiment. He believes the raised guidance and enhanced shareholder returns reflect underlying confidence in both business fundamentals and investor appetite. "With positive news flow and rising profits, demand for GSK shares should remain robust, but the sharp price move warrants attention to possible consolidation in the near term."

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s upward guidance and international expansion as affirming the company’s fundamental recovery. He notes that strong sales in the US and major global markets, strategic R&D investments, and steady buyback activity point to stable institutional backing and operational momentum. "Investors should weigh macroeconomic developments and sector trends, as sustained outperformance depends on broad market support and ongoing execution."

Jainam Mehta, market strategist, takes a cautious stance given the recent volatility and the short-term divergence between momentum and oscillators such as Stoch RSI. He points out that although the outlook appears firm, the sharp price surge and high volatility may signal overextension. "I would treat GSK’s current strength with skepticism, as the potential for a pullback remains elevated despite strong earnings."

Bullish momentum faces mild divergence as conviction wanes

Momentum indicators show strength, with a strong buy signal from the MACD aligning with the bullish trend, but ADX readings indicate some loss of conviction and a potential lack of fresh trend impetus. RSI and CCI remain in buy territory, while Stoch RSI on D1 is oversold, indicating a short-term cooldown within a broader uptrend — this creates a mild divergence between momentum and short-term oscillators. BBP is neutral, suggesting neither buyers nor sellers are dominating intraday swings, while the Awesome Oscillator reinforces the broader upward bias. After a clear gap up from the previous close ($1,644.00) to today’s open ($1,679.70), the price surged $112.00 (6.81%) and is currently trading near the high of today’s range, reflecting high intraday volatility and persistent strength toward session highs.

Previously it was noted that buyback activity and investor accumulation were offset by R&D pipeline risks, with volatility remaining low as the price consolidated in a narrow daily range. Technical indicators showed mixed momentum amid cautious sentiment driven by product developments and regulatory concerns, as highlighted in technical outlook signaled mixed momentum.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.